Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

CX-4945 . hydrochloride [1009820-21-6]

Research Use Only
AG-CR1-3629
AdipoGen Life Sciences
Estimated Purity>98%
Product group Chemicals
Molecular Weight349.8 . 36.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    CX-4945 . hydrochloride [1009820-21-6]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C19H12ClN3O2 . HCl
  • Molecular Weight
    349.8 . 36.5
  • Scientific Description
    Chemical. CAS: 1009820-21-6 (free acid). Formula: C19H12ClN3O2 . HCl. MW: 349.8 . 36.5. Synthetic. Orally active, potent and selective ATP-competitive inhibitor of the protein kinase CK2 (IC50=1nM). Anticancer compound. Inhibits proliferation in a panel of cancer cell lines that overexpress CK2. Inhibited migration, blocks survival and induces apoptosis in cancer stem cells, glioblastomas and leukemia cells. Shown to decrease the glucose metabolism in cancer cells. Potent inhibitor of Cdc2-like kinases (Clks) in vitro, consequently interfering with alternative splicing. Potent ATP-competitive inhibitor of DYRK1A (IC50=6.8 nM), involved in neurodegenration-associated diseases. CK2alpha deletion selectively increased M3 muscarinic receptors (M3Rs)-mediated insulin secretion from pancreatic islets. Promoted cAMP-induced thermogenesis in white adipocytes. CK2 inhibition ameliorates diet-induced obesity and insulin resistance in mice in vivo by promoting UCP1-dependent thermogenesis. - Orally active, potent and selective ATP-competitive inhibitor of the protein kinase CK2 (IC50=1nM). Anticancer compound. Inhibits proliferation in a panel of cancer cell lines that overexpress CK2. Inhibited migration, blocks survival and induces apoptosis in cancer stem cells, glioblastomas and leukemia cells. Shown to decrease the glucose metabolism in cancer cells. Potent inhibitor of Cdc2-like kinases (Clks) in vitro, consequently interfering with alternative splicing. Potent ATP-competitive inhibitor of DYRK1A (IC50=6.8nM), DYRK1B (IC50=6.4nM) and DYRK3 (IC50=18nM), involved in neurodegeneration-associated diseases. CK2alpha deletion selectively increased M3 muscarinic receptors (M3Rs)-mediated insulin secretion from pancreatic islets. Promoted cAMP-induced thermogenesis in white adipocytes. CK2 inhibition ameliorates diet-induced obesity and insulin resistance in mice in vivo by promoting UCP1-dependent thermogenesis.
  • SMILES
    ClC1=CC=CC([NH2+]C2=NC3=CC(C(O)=O)=CC=C3C4=C2C=CN=C4)=C1.[Cl-]
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Structural basis of CX-4945 binding to human protein kinase CK2: A.D. Ferguson, et al.; FEBS Lett. 585, 104 (2011)
  • Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer: F. Pierre, et al.; J. Med. Chem. 54, 635 (2011)
  • Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer: F. Pierre, et al.; Mol. Cell Biochem. 356,37 (2011)
  • CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway: R.C. Prins, et al.; Leukemia 27, 2094 (2013)
  • CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells: M.J. Ku, et al.; Bioorg. Med. Chem. Lett. 23, 5609 (2013)
  • Identification of a novel function of CX-4945 as a splicing regulator: H. Kim, et .al.; PLos One 9, e94978 (2014)
  • Phosphoproteomics identifies CK2 as a negative regulator of beige adipocyte thermogenesis and energy expenditure: K. Shinoda, et al.; Cell Metab. 22, 997 (2015)
  • CK2 acts as a potent negative regulator of receptor-mediated insulin release in vitro and in vivo: M. Rossi, et al.; PNAS 112, E6818 (2015)
  • A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition: H. Kim, et al.; Dis. Model Mech. 9, 839 (2016)
  • Targeting protein kinase CK2 suppresses bladder cancer cell survival via the glucose metabolic pathway: X. Zhang, et al.; Oncotarget. (Epub ahead of print) (2016)